@FierceBiotech: As many as 5 life sciences companies could go public this week, bringing in a combined $115M. News | Follow @FierceBiotech
@JohnCFierce: Really enjoyed talking with One Nucleus members about biotech valuations. Interesting times. | Follow @JohnCFierce
@DamianFierce: The most influential people in biopharma today, according to FierceBiotech. Who'd we miss? Who doesn't belong? | Follow @DamianFierce
@EmilyMFierce: Penn cancer research Carl June made our list of most influential people in biopharma. Profile | Follow @EmilyMFierce
> After last year's rejection of a treatment for female hypoactive sexual desire disorder, the FDA has faced charges of carrying on a gender bias in its approach to libido drugs. Now the agency has fired back, telling Reuters it does not discriminate and has only "engaged in a scientific process in which we evaluated whether the drug's benefits outweigh its risk." More
> Israel's Kamada ($KMDA), a 2013 IPO alum, has seen its shares steadily rise as investors await the results of a Phase II study on its drug for hereditary lung disease. Article
@FierceMedDev: Italian Dx outfit DiaSorin launched a new Rotavirus test in the EU - it could have legs in the developing world, too. Story | Follow @FierceMedDev
@MarkHFierce: Folks, we have a strong new issue of FierceDiagnostics ready for reading. News from Myriad, Brazil and more. Issue | Follow @MarkHFierce
@MichaelGFierce: Who are the most influential people in biopharma today? Check out FierceBiotech's 2014 list. Report | Follow @MichaelGFierce
@EmilyWFierce: King Richard III's genome to be sequenced by researchers at the University of Leicester. Article | Follow @EmilyWFierce
> FDA publishes its warning letter to Baxter over home dialysis and infusion devices. Story
> NC patients exposed to rare, fatal brain disease through dirty surgical tools. More
> Sequoia Capital leads $10M round for cancer Dx startup Guardant Health. Item
> The FDA hit Amgen with a warning over drug/device combo manufacturing violations. News
Pharma News
@FiercePharma: AstraZeneca's stateside comeback for Brilinta has run aground on a DoJ investigation. Story | Follow @FiercePharma
@TracyStaton: Team effort here - The most influential people in biopharma today. Report | Follow @TracyStaton
@EricPFierce: Hospira CEO F. Michael Ball says the FDA has moved its Austin, TX and Rocky Mount, NC facilities to VAI status. | Follow @EricPFierce
@CarlyHFierce: Can't make an influentials list without Valeant CEO J. Michael Pearson - that M&A strategy has made waves. More | Follow @CarlyHFierce
> Gilead backs exuberant analyst projections for new hep C drug. News
> Novartis aims for super-speed with strategic review, CEO tells analysts. Piece
> FDA panel says Aleve should keep its heart-risk warning. Story
Drug Delivery News
> CalTech: Antibody carriers grant HIV protection across mucosal membranes. More
> To fight muscular dystrophy, nanoparticles target cells that choke themselves with waste. Story
> BioDelivery looks for $60M offering to boost addiction film, pain gel. News
> Alnylam, MIT team develops RNA-delivering nanoparticles for the liver. Report
> Nasal vaccine delivery conquers West Nile Virus in fewer doses. Article
> Sonrgy grabs rights to UCSD-created ultrasound-nanocarrier tech. Item
Diagnostics News
> Guardant Health raises $10M and debuts a new blood Dx for personalized cancer treatment. Story
> One Brazilian Dx giant gets new majority shareholders, and another may be sold. News
> Scottish imaging agent startup raises a $6.56 million Series A round. More
> Myriad and Gene By Gene resolve their differences over BRCA cancer Dx tests. Article
> Exact will make its case on March 27 for FDA approval of a colon cancer Dx. Piece
> Alere improves Q4 numbers through revenue growth and cost cuts. Item
Pharma Marketing News
> Steering for a U.S. comeback, AstraZeneca's Brilinta runs aground on DoJ investigation. Story
> Will PBMs turn copay coupons into an endangered species? Article
> Big Pharma legal whiz sees DoJ, FDA crackdown on CEO quotes and press releases. Story
> Feds target Teva in probe of Copaxone, Azilect marketing. News
> Nestlé plans to use its global marketing juju to rev up Galderma. Article
> New NICE advice could put millions more U.K. patients on statins. Item